Evidence map›Paper›PMID 41611879›Full record

ArticleApplied microbiology and biotechnology2026

An integrated cell and medium engineering approach for production of a nanobody fusion in Saccharomyces cerevisiae.

Laura R K Niemelä, Lotta-Mari Kirjavainen, Hendrikje C J Kozlowski, Heidi Salminen, Alexander D Frey

Abstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laura R K NiemeläDepartment of Bioproducts and Biosystems, Aalto University, Espoo, Finland.
Lotta-Mari KirjavainenDepartment of Bioproducts and Biosystems, Aalto University, Espoo, Finland.
Hendrikje C J KozlowskiDepartment of Bioproducts and Biosystems, Aalto University, Espoo, Finland.
Heidi SalminenDepartment of Bioproducts and Biosystems, Aalto University, Espoo, Finland.
Alexander D FreyDepartment of Bioproducts and Biosystems, Aalto University, Espoo, Finland. alexander.frey@aalto.fi.ORCID http://orcid.org/0000-0002-4371-0227

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Saccharomyces cerevisiae is an established production host for therapeutic proteins; many of those are small proteins such as insulin or glucagon-like peptide-1 (GLP-1) analogs. Contrastingly, proteins of higher molecular weight, foremost antibodies, did not reach the market due, among other factors, to limiting productivity. Here we addressed the loss of product to protein degradation through a combination of genetic engineering of the host and medium optimization. We screened target genes that either directly or indirectly can lead to proteolytic degradation. We identified four deletions that are beneficial for expression: PEP1 and VPS30, which both can channel proteins to the vacuole for degradation; MON2, which can lead to the re-uptake of secreted proteins; and ALG3, which can affect the permeability of the cell wall. In parallel, we developed a small-scale fed-batch cultivation system for 24-well deep well plate cultivations and using an amino acid-rich medium. To stabilize secreted proteins, we screened chemical chaperones and osmolytes. We fortified the medium with arginine, 4-phenylbutyrate (4-PBA), and Tween-20. Using the engineered yeast strain, which features VPS30, PEP1, and ALG3 deletions, and the small-scale fed-batch system, we obtained 2.5 µg/mL of a secreted chimeric fusion of a nanobody to the crystallizable fragment (Fc) of a human immunoglobulin. Instrumental to the increase in the final titer were the reduced losses. This was achieved by a combination of complementary measures: improving diffusion through the cell wall, achieved through genetic engineering, and reducing losses to proteolytic degradation through medium optimization and genetic engineering. Moreover, we showed that the engineered strain and cultivation set-up are suitable for the production of different antibodies. KEY POINTS: • Chemical chaperones and amino acid-rich medium increased secreted protein titers. • Medium and host engineering are instrumental for improving productivity. • Small-scale cultivation system enables production levels suitable for characterization.

Indexed as

Culture MediaMetabolic EngineeringRecombinant Fusion ProteinsSaccharomyces cerevisiaeSingle-Domain AntibodiesBatch Cell Culture TechniquesGenetic EngineeringProteolysisSaccharomyces cerevisiae ProteinsCulture MediaRecombinant Fusion ProteinsSaccharomyces cerevisiae ProteinsSingle-Domain AntibodiesChemical chaperonesChimeric nanobody-Fc fusion proteinMedium optimizationRecombinant antibody productionSaccharomyces cerevisiaeSmall-scale production system

Identifiers

PMID41611879
PMCPMC12858493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.